Large-scale cancer genomics and genome-wide studies of the chromatin and DNA methylation landscape are reshaping our understanding of tumor heterogeneity, evolution, and genome stability. It is clear that epigenetic regulators are critical mediators of cancer progression and drug resistance, and new classes of targeted therapeutics against epigenetic regulators are already in clinical trials.

Our goal in organizing this meeting is to gather together experts on cancer, genomics, chromatin, systems biology, and chemical biology to discuss the rapidly advancing field of cancer epigenomics and its imminent impact on new cancer therapies. We aim to provide a forum for discussion and potential future collaboration amongst clinicians, drug development companies, and those at the forefront of basic biological discovery. The ultimate goal is to advance this exciting aspect of cancer biology and inform the epigenetic cancer therapies of tomorrow.